{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:06:30Z","timestamp":1793239590215,"version":"4.5.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Lupus nephritis is a common complication of systemic lupus erythematosus and is associated with significant morbidity and mortality. The utility of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the management of lupus nephritis is currently uncertain. Here, we summarize the rationale for their use among patient with lupus nephritis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>SGLT2 inhibitors were initially developed as antihyperglycemic agents. They have since been shown to have additional, profound effects to slow the progression of chronic kidney disease and lessen the long-term risks of cardiovascular disease in large clinic trials of patients with chronic kidney disease, with and without diabetes, as well as in patients with and without proteinuria. Patients with recent exposure to immunosuppression were excluded from these trials due to concern for risk of infection. In the few, small trials of patients with lupus nephritis, SGLT2 inhibitors were found to be well tolerated. They have been shown to reduce proteinuria and to have modest beneficial effects on blood pressure and BMI among patients with lupus nephritis. They have not been shown to influence disease activity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>SGLT2 inhibitors may have a role in mitigating the chronic renal and cardiovascular effects of lupus nephritis. They should be introduced after kidney function has been stabilized with appropriate immunosuppression, in conjunction with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. They currently have no role in active disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001002","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T15:01:16Z","timestamp":1711119676000},"page":"163-168","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Sodium-glucose cotransporter 2 inhibitors: are they ready for prime time in the management of lupus nephritis?"],"prefix":"10.1097","volume":"36","author":[{"given":"Benjamin R.","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panduranga S.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/dom.12073","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks\u2019 treatment with empagliflozin once daily in patients with type 2 diabetes","volume":"15","author":"Heise","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A prespecified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/annrheumdis-2021-221474","article-title":"Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors","volume":"81","author":"S\u00e4emann","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/0148607104028005364","article-title":"The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function","volume":"28","author":"Scheepers","year":"2004","journal-title":"J Parenter Enter Nutr"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","article-title":"Localizations of Na+-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart","volume":"467","author":"Vrhovac","year":"2015","journal-title":"Pfl\u00fcg Arch Eur J Physiol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41584-023-01024-1","article-title":"SGLT2 inhibitors protect podocytes in lupus nephritis","volume":"19","author":"Onuora","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1681\/ASN.2009070759","article-title":"Macula densa sensing and signaling mechanisms of renin release","volume":"21","author":"Peti-Peterdi","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1536\/ihj.37.153","article-title":"Tubuloglomerular feedback","volume":"37","author":"Ito","year":"1996","journal-title":"Jpn Heart J"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.ekir.2021.05.022","article-title":"Markers of kidney injury, inflammation, and fibrosis associated with ertugliflozin in patients with CKD and diabetes","volume":"6","author":"Liu","year":"2021","journal-title":"Kidney Int Rep"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.kint.2020.02.041","article-title":"The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?","volume":"98","author":"Hesp","year":"2020","journal-title":"Kidney Int"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/jdi.13009","article-title":"Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats","volume":"10","author":"Kimura","year":"2019","journal-title":"J Diabetes Investig"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-023-04663-y","article-title":"The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice","volume":"6","author":"Choi","year":"2023","journal-title":"Commun Biol"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.cmet.2023.05.001","article-title":"Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity","volume":"35","author":"Jenkins","year":"2023","journal-title":"Cell Metab"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11886-021-01626-9","article-title":"Cardiovascular outcomes in systemic lupus erythematosus","volume":"24","author":"Sairam","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"107466","DOI":"10.1016\/j.intimp.2021.107466","article-title":"Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: a systematic review and meta-analysis","volume":"94","author":"Lu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jacc.2021.02.029","article-title":"Long-term cardiovascular outcomes in systemic lupus erythematosus","volume":"77","author":"Yafasova","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/heartjnl-2016-309561","article-title":"Incidence and risk of heart failure in systemic lupus erythematosus","volume":"103","author":"Kim","year":"2017","journal-title":"Heart"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3899\/jrheum.191064","article-title":"Advanced chronic kidney disease in lupus nephritis: is dialysis inevitable?","volume":"47","author":"Tselios","year":"2020","journal-title":"J Rheumatol"},{"key":"R36-20250526","first-page":"e895","article-title":"2022\u200aAHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"104215","DOI":"10.1016\/j.ebiom.2022.104215","article-title":"Cardiorenal protection of SGLT2 inhibitors\u2014perspectives from metabolic reprogramming","volume":"83","author":"Gao","year":"2022","journal-title":"eBioMedicine"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"e002686","DOI":"10.1136\/rmdopen-2022-002686","article-title":"Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I\/II trial","volume":"8","author":"Wang","year":"2022","journal-title":"RMD Open"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/ard-2023-224242","article-title":"SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy","volume":"82","author":"Zhao","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"1105676","DOI":"10.3389\/fneph.2023.1105676","article-title":"Lupus nephropathy beyond immunosuppression: searching for nephro and cardioprotection","volume":"3","author":"Morales","year":"2023","journal-title":"Front Nephrol"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"i401","DOI":"10.1093\/ndt\/gfad063c_5217","article-title":"Protocol and preliminary results of dapagliflozin in inactive lupus nephritis cross-over randomized trial","volume":"38","author":"Vajgel","year":"2023","journal-title":"Nephrol Dial Transplant"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:17:56Z","timestamp":1748294276000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001002","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]}}}